Portal de Periódicos da CAPES

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

2023; Elsevier BV; Volume: 4; Issue: 10 Linguagem: Inglês

10.1016/j.medj.2023.07.007

2666-6359

Timothée Bruel, Lou-Léna Vrignaud, Françoise Porrot, Isabelle Staropoli, Delphine Planas, Florence Guivel‐Benhassine, Julien Puech, Matthieu Prot, Sandie Munier, William Bolland, Cathia Soulié, Karen Zafilaza, Clovis Lusivika‐Nzinga, Marie-Laure Meledge, Céline Dorival, Diana Molino, Hélène Péré, Youri Yordanov, Etienne Simon‐Lorière, David Veyer, Fabrice Carrat, Olivier Schwartz, Anne‐Geneviève Marcelin, Guillaume Martin‐Blondel, Magalie Garcia, Valentin Giraud, Agathe Metais, Fance Cazenave-Roblot, Jean-Philippe Martellosio Anne-Marie Ronchetti, Thomas Gabas, Naima Hadjadj, Célia Salanoubat, Amélie Chabrol, P Housset, Agathe Pardon, Anne‐Laure Faucon, Valérie Caudwell, L Liblau, Laurent Alric, G. Pugnet, M. Mourguet, Eva Bories, Delphine Bonnet, Sandrine Charpentier, Pierre Delobel, Alexa Debard, Colleen Beck, X. Boumaza, Stella Rousset Fanny Lanternier, Claire Delage, Elisabete Gomes Pires, Morgane Cheminant, N. Chauvin, Xavier Eyer Véronique Delcey Simon Bessis, Mélanie Cresta, Romain Gueneau Pélagie Thibaut, Marine Nadal, Martin Siguier, Marwa Bachir, Christia Palacios Valérie Pourcher, Cléa Melenotte, Antoine Fayçal, V. Bérot, C. Brin, Siham Djebara, Karen Zafilaza, Stéphane Marot, Sophie Sayon, Vincent Leducq, Isabelle Malet, Elisa Teyssou, Adélie Gothland Karine Lacombe, Yasmine Abi Aad, Thibault Chiarabini, Raynald Feliho, Nadia Valin, Fabien Brigant, Julien Boize, Pierre‐Clément Thiebaud, Marie Moreau, Charlotte Billard Nathalie De Castro, Geoffroy Liégeon, Blandine Denis, Jean‐Michel Molina, Lucia Etheve André Cabié, Sylvie Abel, Ornella Cabras, K Guitteaud, Sandrine Pierre- François Vincent Dubee, Diama Ndiaye, Jonathan Pehlivan, Michael Phelippeau, Rafael Mahieu Alexandre Duvignaud, Thierry Pistone, Arnaud Desclaux, D. Neau, Charles Cazanave Jean-François Faucher, Benjamin Festou, Magali Dupuy-Grasset, V. Loustaud‐Ratti, Delphine Chainier Nathan Peiffer- Smadja, Christophe Choquet, O. Da Conceiçao, Michaël Thy, Lio Collas, C. Godard, Donia Bouzid, Vittiaroat Ing, Laurent Pereira, Thomas Pavlowsky, Camille RavautAntoine Asquier-Khati, D. Boutoille, Marie Chauveau, Colin Deschanvres, F Bot, M. Cailleaux, François Bénézit, Anne Maillard, B. Hue, Pierre Tattevin François Coustilleres, Claudia Carvalho-Schneider, Simon Jamard, Laëticia Petit, Karl Stefic Natacha Mrozek, Clément Theis, M. Vidal, Léo Sauvat, Delphine Martineau Benjamin Lefèvre, Guillaume Baronnet, Agnès Didier Florence Ader, Thomas Perpoint, Anne Conrad, Paul Chabert, Pierre Chauvelot Aurélie Martin, Paul Loubet, Julien Mazet, Romaric Larcher, Didier Laureillard Mathilde Devaux Jérôme Frey, Amos Woerlen, Aline Remillon, Laure Absensur-Vuillaume, Pauline Bouquet Albert Trinh-Duc, Patrick Rispal Philippe Petua, Julien Carillo Aurore Perrot, K. Delavigne, P. Cougoul, Jérémie Dion, Odile Rauzy Mathieu Blot, Thibault Sixt, Florian Moretto, Carole Charles, Lionel Piroth Sophie Circosta, Lydia Leger, A. Arulananthan, Carine Lascoux, Pascaline Valérie, Leia Becam Yazdan Yazdanpanah, Ventzislava Petrov–Sanchez, Alpha Diallo, Soizic Le Mestre, Guillaume Le Meut Isabelle Goderel, Frédéric Chau, Brahim Soltana, Jessica Chane Tang, Jérémie Guedj, Yvanie Caillé,

Immunotherapy and Immune Responses

Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants. Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.